In a video by Catherine Lai, MD, MPH at the ASH Annual Meeting, a study on FLT-3 inhibitors in leukemia patients with FLT-3 mutations was discussed. The study compared the effectiveness of midostaurin, quizartinib, and gilteritinib in treating these patients. Lai highlighted that while midostaurin and quizartinib are approved in the newly diagnosed setting, gilteritinib is showing promise due to its well-tolerated nature and different side effect profile. Lai, an assistant professor at the University of Pennsylvania, also disclosed her associations with various companies in the healthcare industry.
Source link
Study examines FLT-3 inhibitors in leukemia treatment
